Acumen Pharmaceuticals (ABOS) Total Current Liabilities (2021 - 2026)

Acumen Pharmaceuticals (ABOS) has 6 years of Total Current Liabilities data on file, last reported at $29.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 51.33% year-over-year to $29.2 million; the trailing twelve-month figure through Mar 2026 stood at $29.2 million (up 51.33% YoY), and the FY2025 full-year result was $30.0 million, up 8.69% from the prior year.
• Total Current Liabilities slipped to $29.2 million in Q1 2026, from $30.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $30.0 million in Q4 2025 to a low of $3.9 million in Q1 2022.
• A 5-year average of $15.1 million and a median of $13.0 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities retreated 7.79% in 2023 and jumped 226.57% in 2024, its largest moves.
• Tracing ABOS's Total Current Liabilities over 5 years: stood at $7.8 million in 2022, then soared by 66.04% to $13.0 million in 2023, then surged by 112.84% to $27.6 million in 2024, then grew by 8.69% to $30.0 million in 2025, then decreased by 2.59% to $29.2 million in 2026.
• Business Quant data shows ABOS's Total Current Liabilities at $29.2 million in Q1 2026, $30.0 million in Q4 2025, and $22.0 million in Q3 2025.